Scancell Holdings PLC (GB:SCLP)
LSE:SCLP
Want to see GB:SCLP full AI Analyst Report?
SCLP Stock Chart & Stats
9.75 p
0.40 p(4.06%)
At close: 4:00 PM EST
9.75 p
0.40 p(4.06%)
Day’s Range― - ―
52-Week Range7.86 p - 29.50 p
Previous CloseN/A
Volume797.06K
Average Volume (3M)1.20M
Market Cap
£246.47M
Enterprise Value255.64M
Total Cash (Recent Filing)£8.57M
Total Debt (Recent Filing)£16.18M
Price to Earnings (P/E)―
Beta>-0.01
Next Earnings
Oct 23, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,037,781,400
10 Day Avg. Volume991,653
30 Day Avg. Volume1,200,950
Financial Highlights & Ratios
PEG Ratio-0.10
Price to Book (P/B)-27.20
Price to Sales (P/S)22.14
P/FCF Ratio-17.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.02
Revenue Forecast (FY)£1.20M
Bulls Say, Bears Say
Bulls Say
Compelling Phase II Efficacy SignalA strong PFS signal from Phase II materially raises the probability of clinical success and partner interest. Over the medium term this supports a credible registrational strategy, strengthens negotiating leverage for licensing/milestones and de-risks development compared with programs lacking such translational evidence.
FDA IND Cleared For Phase III Registrational TrialRegulatory acceptance of dose, design and a surrogate endpoint meaningfully lowers regulatory uncertainty and shortens potential commercial timelines via accelerated approval. This durable regulatory progress validates development strategy and enhances the program's attractiveness to partners and investors.
Partnered Pipeline Depth And Commercial EnablersA diversified pipeline plus meaningful partnered upside and commercial enablers (manufacturing scale, device partnership) reduce execution risk and provide non-dilutive financing paths. Material Genmab milestones and device/commercial readiness are structural positives for long-term value capture.
Bears Say
Negative Shareholder EquityPersistently negative equity and modest asset base constrain financial flexibility and make leverage ratios less meaningful. Over months this weak capital structure amplifies refinancing risk, limits ability to fund expensive Phase III activities internally and increases dependency on partner deals or dilutive financing.
Limited Cash Runway Into H2 2026A short cash runway ahead of a costly Phase III forces near-term financing or deal-making. This pressure can compel less favorable partnership terms, increase dilution risk, and may disrupt development pacing if milestone receipts or financings are delayed, posing a durable funding overhang until secured.
Long Blinded Phase III TimelineA multi-year, blinded registrational trial extends the period of execution risk and capital intensity. Limited interim visibility increases uncertainty for partners and investors, raises the chance that competitive or regulatory landscapes shift, and prolongs reliance on external funding or milestone events to sustain operations.
Scancell Holdings News
SCLP FAQ
What was Scancell Holdings PLC’s price range in the past 12 months?
Scancell Holdings PLC lowest share price was 7.86 p and its highest was 29.50 p in the past 12 months.
What is Scancell Holdings PLC’s market cap?
Scancell Holdings PLC’s market cap is £246.47M.
When is Scancell Holdings PLC’s upcoming earnings report date?
Scancell Holdings PLC’s upcoming earnings report date is Oct 23, 2026 which is in 140 days.
How were Scancell Holdings PLC’s earnings last quarter?
Scancell Holdings PLC released its earnings results on Jan 29, 2026. The company reported -0.006 p earnings per share for the quarter, missing the consensus estimate of N/A by -0.006 p.
Is Scancell Holdings PLC overvalued?
According to Wall Street analysts Scancell Holdings PLC’s price is currently Overvalued.
Does Scancell Holdings PLC pay dividends?
Scancell Holdings PLC does not currently pay dividends.
What is Scancell Holdings PLC’s EPS estimate?
Scancell Holdings PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Scancell Holdings PLC have?
Scancell Holdings PLC has 1,037,781,400 shares outstanding.
What happened to Scancell Holdings PLC’s price movement after its last earnings report?
Scancell Holdings PLC reported an EPS of -0.006 p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.804%.
Which hedge fund is a major shareholder of Scancell Holdings PLC?
Currently, no hedge funds are holding shares in GB:SCLP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Scancell Holdings Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-29.25%
12-Months-Change
Fundamentals
Return on Equity
90.29%
Trailing 12-Months
Asset Growth
-7.40%
Trailing 12-Months
Company Description
Scancell Holdings PLC
Scancell Holdings plc, a clinical stage biopharmaceutical company, engages in the discovery and development of novel vaccines and antibody medicines to treat unmet needs in cancer and infectious diseases. The company's product candidates include SCIB1, which is in phase II clinical trial for the treatment of metastatic melanoma; SCIB2 for the treatment of non-small cell lung cancer; and Modi-1 that is in phase I/II clinical trials for the treatment of head and neck, triple negative breast, ovarian, and renal cancers. It also develops Modi-2, which targets homocitrullinated cancer antigens. In addition, the company develops SCOV1 and SCOV2 COVIDITY, a prophylactic DNA vaccine against the SARS-CoV-2 virus. Scancell Holdings plc was founded in 1997 and is based in Oxford, the United Kingdom.
Technical Analysis
Sareum Holdings
―
4basebio UK Societas
―
Poolbeg Pharma Ltd.
―
Arecor Therapeutics PLC
―
Ondine Biomedical, Inc.
―
Options Prices
Currently, No data available
---